Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 19/20 | 0.66 |
| ▸ | ICAM1 | P05362 | 19/20 | 0.66 |
| ▸ | ITGAL | P20701 | 19/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.46 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20903203 | 1.00 | ITGB2 (0.66) | ITGB2ICAM1ITGALCYP2C9ITGB1 | |
| Hydrochloric Acid SCHEMBL20680587 | 0.99 | ITGB2 (0.65) | ITGB2ICAM1ITGALCYP2C9ITGB1 | |
| Hydrochloric Acid SCHEMBL20680588 | 0.99 | ITGB2 (0.65) | ITGB2ICAM1ITGALCYP2C9ITGB1 | |
| SCHEMBL15445340 | 0.93 | ITGB2 (0.59) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL19134129 | 0.92 | ITGB2 (0.57) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL21003968 | 0.92 | ITGB2 (0.56) | ITGB2ICAM1ITGALCYP2C9ITGB1 | |
| Hydrochloric Acid SCHEMBL29547703 | 0.91 | ITGB2 (0.55) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL13588337 | 0.90 | ITGB2 (0.55) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL20833731 | 0.90 | ITGB2 (0.55) | ITGB2ICAM1ITGALCYP2C9 | |
| Hydrochloric Acid SCHEMBL31021044 | 0.90 | ITGB2 (0.55) | ITGB2ICAM1ITGALCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3807268-B1 | PROCESS FOR THE PREPARATION OF LIFITEGRAST | OLON SPA (IT) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022084739-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2022-04-28 | — | — | WO | disclosed |
| US-11286250-B2 | Process for preparing and purifying a LFA-1 antagonist | INTERQUIM, S.A. (ES) | 2022-03-29 | — | — | US | disclosed |
| US-11246862-B2 | Process for the preparation of lifitegrast | MANKIND PHARMA LTD. (IN) | 2022-02-15 | — | — | US | disclosed |
| US-11246862-B2 | Process for the preparation of lifitegrast | MANKIND PHARMA LTD. (IN) | 2022-02-15 | — | — | US | disclosed |
| US-20210145824-A1 | MODULATORS OF CELLULAR ADHESION | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2021-05-20 | — | — | US | disclosed |
| US-11001574-B2 | Process to obtain a tetrahydroisoquinoline derivative | MEDICHEM S.A. (ES) | 2021-05-11 | — | — | US | disclosed |
| EP-3658549-B1 | PROCESS FOR PREPARING AND PURIFYING THE LFA-1 ANTAGONIST LIFITEGRAST | INTERQUIM SA (ES) | 2021-05-05 | — | — | EP | disclosed |
| EP-3797775-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | Novartis AG (CH) | 2021-03-31 | — | — | EP | disclosed |
| US-20200369652-A1 | PROCESSES FOR PREPARATION OF LIFITEGRAST AND INTERMEDIATES THEREOF | DR. REDDY'S LABORATORIES LIMITED (IN) | 2020-11-26 | — | — | US | disclosed |
| US-7745460-B2 | Modulators of cellular adhesion | SARCODE CORPORATION (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745460-B2 | Modulators of cellular adhesion | SARCODE CORPORATION (US) | 2010-06-29 | — | — | US | disclosed |
| US-20100093693-A1 | MODULATORS OF CELLULAR ADHESION | BAUSCH + LOMB IRELAND LIMITED (IE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093693-A1 | MODULATORS OF CELLULAR ADHESION | BAUSCH + LOMB IRELAND LIMITED (IE) | 2010-04-15 | — | — | US | disclosed |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080176896-A1 | Modulators of cellular adhesion | BAUSCH + LOMB IRELAND LIMITED (IE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176896-A1 | Modulators of cellular adhesion | BAUSCH + LOMB IRELAND LIMITED (IE) | 2008-07-24 | — | — | US | disclosed |
| US-7314938-B2 | Immune and/or inflammatory disorders; autoimmune disorders; disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1); antagonize CD11/CD18 receptors associated with leukocytes. | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314938-B2 | Immune and/or inflammatory disorders; autoimmune disorders; disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1); antagonize CD11/CD18 receptors associated with leukocytes. | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210145824-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | ITGB2 8/4885ICAM1 5/4885ITGAL 11/4885 |
| US-20080176896-A1 | Modulators of cellular adhesion | ITGB1, VCAM1, ITGB8 | ITGB2 8/4885ICAM1 5/4885ITGAL 11/4885 |
| US-11246862-B2 | Process for the preparation of lifitegrast | LIFR, PTGFR, CSF1R | ITGB2 839/4885ICAM1 4016/4885ITGAL 527/4885 |
| US-11286250-B2 | Process for preparing and purifying a LFA-1 antagonist | LIFR, ITGA1, ITGAL | ITGB2 13/4885ICAM1 75/4885ITGAL 3/4885 |
| US-20100093693-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | ITGB2 8/4885ICAM1 5/4885ITGAL 11/4885 |
| US-20200369652-A1 | PROCESSES FOR PREPARATION OF LIFITEGRAST AND INTERMEDIATES THEREOF | LIFR, FLT3, CSF3R | ITGB2 951/4885ICAM1 4625/4885ITGAL 443/4885 |
| US-11001574-B2 | Process to obtain a tetrahydroisoquinoline derivative | KCNQ5, KCNQ4, KCNQ2 | ITGB2 3390/4885ICAM1 4655/4885ITGAL 2789/4885 |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | ITGB2 8/4885ICAM1 5/4885ITGAL 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.